The Radiobiological Case for Alpha over Beta in PSMA-Targeted Therapy
Actinium-225 delivers approximately 5–8 Sv per disintegration with a mean free path of 50–80 micrometers and a linear energy transfer (LET) of 80–100 keV/μm — roughly 400–500 times the LET of lutetium-177, which emits beta particles at just 0.2 keV/μm with a tissue path length up to 2 mm. This is not a marginal difference: high-LET alpha radiation induces clustered DNA double-strand breaks that are substantially harder for cancer cells to repair than the single-strand breaks produced by beta emitters, conferring far greater cytotoxicity per unit absorbed dose.
The short tissue range of alpha particles — 50–80 micrometers, or roughly the diameter of one to two cell diameters — is both an advantage and a limitation. It confers highly localised tumour killing with reduced bone marrow toxicity compared to Lu-177's longer-range beta emission, making Ac-225 particularly well-suited to the micrometastatic disease and bone marrow involvement that characterise advanced mCRPC. According to dosimetric analyses published in the European Journal of Nuclear Medicine and Molecular Imaging, this short-range precision also means Ac-225 is advantaged for micrometastatic disease where Lu-177's crossfire effect may be insufficient.
Approximately 20–25% of mCRPC patients are PSMA-low or PSMA-negative and ineligible for PSMA radioligand therapy. Within PSMA-positive tumours, intratumoral heterogeneity of PSMA expression may drive resistance to beta-emitter therapy through outgrowth of PSMA-negative clones. High-LET alpha therapy from Ac-225 may overcome this limitation through its crossfire effect and bystander killing capacity, as demonstrated in PET imaging studies of 312 mCRPC patients.
The primary chelation chemistry employed for Ac-225 is DOTA-based, using the same PSMA-617 scaffold as the approved Lu-177 agent. However, DOTA's kinetic inertness under Ac-225 conditions is suboptimal — a recognised limitation that has motivated a parallel wave of chelator innovation. Daughter radionuclides of Ac-225 (notably francium-221 and bismuth-213) can redistribute to non-targeted tissues if chelation is inadequate, a problem not present with Lu-177. This chemistry challenge, and the patent activity it has generated, is a defining feature of the current Ac-225 landscape.
Actinium-225 delivers alpha particles with a linear energy transfer of 80–100 keV/μm and a mean free path of 50–80 micrometers, compared to lutetium-177's beta-particle LET of 0.2 keV/μm and path length up to 2 mm — a difference of approximately 400–500-fold in ionising density.
Clinical Evidence: PSA50 Rates, Survival, and Toxicity Head-to-Head
The most consequential clinical comparison in this space comes from a retrospective cohort of 108 mCRPC patients with PSMA-positive disease, in which PSA50 response rates were 87% with Ac-225 PSMA-617 versus 52% with Lu-177 PSMA-617 (p<0.001), and median progression-free survival favoured Ac-225 at 14.2 versus 8.9 months. These figures must be interpreted in the context of the approved standard: the landmark VISION phase 3 trial (n=831) established Lu-177 PSMA-617 plus standard of care as superior to standard of care alone, with median overall survival of 15.3 versus 11.3 months (HR 0.62), radiographic progression-free survival of 8.7 versus 3.4 months (HR 0.40), and PSA50 response in 46% of patients — data that led to FDA approval of Pluvicto.
In a retrospective comparative cohort of 108 mCRPC patients, PSA50 response rates were 87% with Ac-225 PSMA-617 versus 52% with Lu-177 PSMA-617 (p<0.001), with median progression-free survival of 14.2 months versus 8.9 months respectively.
The phase I dose-escalation study of Ac-225 PSMA-617 in 14 mCRPC patients — a small but important early dataset — reported PSA50 responses in 71% of patients at optimal dosing levels, with no dose-limiting hematologic toxicities observed. The primary toxicity across all Ac-225 cohorts is xerostomia (dry mouth), driven by PSMA expression in salivary glands. A systematic review found xerostomia incidence ranging from 45–87% across published Ac-225 PSMA-617 cohorts, compared to just 3% with Lu-177 in the comparative cohort. This toxicity differential is the central clinical trade-off of the alpha-versus-beta debate.
"Grade 2–3 xerostomia was significantly more frequent with Ac-225 (68%) versus Lu-177 (3%) — the central clinical trade-off that defines the alpha-versus-beta debate in PSMA radioligand therapy."
Proposed mitigation strategies for salivary gland toxicity include pre-administration of botulinum toxin injection to reduce salivary gland uptake, cryotherapy during infusion, PSMA antibody pre-blocking of salivary gland PSMA, and fractionated dosing approaches. None of these strategies has yet been validated in a randomised trial per the retrieved literature. The toxicity management challenge is therefore an active area of both clinical investigation and, as discussed below, patent activity around next-generation PSMA ligand design aimed at improving tumour-to-salivary gland ratios.
Track the full Ac-225 PSMA clinical pipeline, patent filings, and competitive intelligence in real time.
Explore the Pipeline in PatSnap Eureka →The Broader Pipeline: Sequential Therapy, Alternative Emitters, and Immunotherapy Combinations
Beyond the direct Ac-225 versus Lu-177 comparison, three distinct strategic directions are emerging in the PSMA RLT pipeline — each supported by both clinical data and patent filings in the retrieved dataset.
Sequential Alpha-Beta Therapy
A prospective observational cohort of 45 mCRPC patients who had progressed on Lu-177 PSMA-617 reported a PSA50 response of 62% to subsequent Ac-225 PSMA-617 salvage therapy, including patients with prior Lu-177 resistance. The mechanistic explanation is compelling: beta-emitter resistance is driven primarily by outgrowth of PSMA-negative clones that are inadequately irradiated by Lu-177's lower-LET, longer-range emission. Alpha particles' clustered double-strand break profile and crossfire/bystander killing capacity can eliminate these resistant subpopulations. This sequential approach — Lu-177 first, Ac-225 as rescue — is increasingly positioned not as a fallback but as a deliberate treatment architecture.
In a prospective observational cohort of 45 mCRPC patients who progressed on Lu-177 PSMA-617, subsequent Ac-225 PSMA-617 salvage therapy produced a PSA50 response rate of 62%, demonstrating that alpha therapy can overcome beta-emitter resistance.
Alternative Alpha Emitters: Terbium-149 and Bismuth-213
Patent filings from the Paul Scherrer Institute disclose PSMA-targeting constructs labelled with terbium-149 (Tb-149) and bismuth-213 (Bi-213) as alternatives to Ac-225. Tb-149 is notable for enabling a theranostic quadruplet: Tb-149 for alpha therapy, Tb-152 for PET imaging, Tb-155 for SPECT imaging, and Tb-161 for beta therapy — a single-element theranostic framework with no equivalent in the Ac-225 space. Bi-213, the primary alpha-emitting daughter of Ac-225, is also being evaluated as a direct labelling agent, potentially offering simpler radiochemistry and a shorter half-life. Preclinical data show comparable tumour-killing efficacy with Tb-149 versus Ac-225, with potentially more favourable daughter nuclide redistribution profiles.
Combination with Immune Checkpoint Inhibitors
High-LET alpha irradiation of PSMA-expressing prostate cancer cells with Ac-225 PSMA-617 induced significantly higher levels of calreticulin surface exposure, HMGB1 release, and ATP secretion compared to equivalent-dose beta-irradiation with Lu-177 PSMA-617 in published research from Cancer Research. These immunogenic cell death (ICD) markers correlated with CD8+ T cell priming in co-culture assays, providing mechanistic rationale for combining Ac-225 PSMA therapy with anti-PD-1, anti-PD-L1, and anti-CTLA-4 checkpoint inhibitors. AstraZeneca has filed a patent covering exactly this combination in mCRPC, and preclinical data from syngeneic prostate tumour models demonstrate synergistic tumour regression and CD8+ T cell infiltration versus monotherapy.
Fusion Pharmaceuticals has filed patents for bi-specific constructs targeting both PSMA and fibroblast activation protein (FAP) for enhanced tumour stroma penetration in mCRPC. The dual-targeting approach aims to overcome PSMA expression heterogeneity and improve therapeutic coverage of the tumour microenvironment, with constructs designed for labelling with both Lu-177 (beta) and Ac-225 (alpha) radionuclides.
The convergence of alpha-particle-induced immunogenic cell death with checkpoint immunotherapy represents a mechanistically coherent combination hypothesis — one that is increasingly attracting both academic investigation and commercial patent protection. The key unresolved question is whether the immunosuppressive microenvironment of mCRPC, well-documented in Nature Medicine and related literature, can be sufficiently reversed by alpha-particle ICD to make checkpoint blockade clinically meaningful in this setting.
The Supply Chain Bottleneck Threatening Ac-225 Scale-Up
Global actinium-225 production capacity stands at approximately 1,800 Ci/year as of 2023 — derived predominantly from uranium-233 decay at Oak Ridge National Laboratory (ORNL) in the United States and Bhabha Atomic Research Centre (BARC) in India. Projected demand from ongoing clinical trials and anticipated commercial programmes could reach 5,000–8,000 Ci/year by 2027–2030, implying a supply gap of roughly three- to four-fold within this decade.
Global actinium-225 production capacity is approximately 1,800 Ci/year as of 2023, predominantly from uranium-233 decay at Oak Ridge National Laboratory and Bhabha Atomic Research Centre. Projected demand from clinical programmes could reach 5,000–8,000 Ci/year by 2027–2030, representing a critical supply bottleneck to widespread clinical adoption.
This is not a theoretical constraint. Current Ac-225 supply is already limiting patient access in investigator-initiated trials and is a primary reason why Ac-225 PSMA programmes have not yet reached the scale of the VISION trial. The supply situation contrasts sharply with Lu-177, which is produced in nuclear reactors at multiple global sites and is commercially available at scale. Patent activity from Eckert and Ziegler SE covers large-scale Ac-225 production via radium-226 proton irradiation at cyclotron facilities and linear accelerator methods — new production routes that are evaluated as potential solutions to the bottleneck. A projected global demand of more than 10 Ci/year by 2027 for PSMA RLT clinical programmes alone is cited in this filing.
The supply challenge has direct implications for the competitive dynamics between Ac-225 and Lu-177. Even if Ac-225 PSMA-617 achieves phase 3 regulatory approval, access will be constrained by isotope availability for years. This creates a structural window for Lu-177 PSMA-617 to consolidate market position, and for combination and sequential strategies that use Ac-225 parsimoniously as a rescue or intensification agent rather than a first-line replacement. Organisations with secured Ac-225 supply agreements — or proprietary production capacity — will hold a significant competitive advantage. According to analyses published by IAEA, the development of new cyclotron-based radium-226 irradiation routes is critical to bridging this gap.
Map the full Ac-225 supply chain patent landscape and identify key players with PatSnap Eureka.
Search Ac-225 Supply Patents in PatSnap Eureka →Patent Landscape: Who Is Filing and What Is Being Protected
The patent landscape for Ac-225 PSMA radioligand therapy in mCRPC is characterised by activity across four distinct technical layers: (1) therapeutic compositions and methods, (2) chelation chemistry, (3) isotope production, and (4) combination strategies. Major pharmaceutical, radiopharmaceutical, and academic organisations have staked out positions across all four.
Therapeutic Compositions and Methods
Bayer AG has filed US patents covering targeted alpha therapy compositions using Ac-225 labelled PSMA ligands, with preclinical data showing significantly improved tumour regression compared to Lu-177 PSMA-617 in xenograft models. Novartis AG — the commercial holder of approved Lu-177 PSMA-617 (Pluvicto) — has filed both WO patents covering Ac-225 PSMA inhibitor compositions and US patents covering Lu-177 PSMA-617 dosing schedules (7.4 GBq every 6 weeks for up to 6 cycles) and combination strategies with androgen receptor pathway inhibitors. RadioMedix Inc. holds EP patents on radiopharmaceutical compositions with novel bifunctional chelators designed to minimise daughter radioisotope redistribution. The presence of Novartis in both the approved Lu-177 space and the emerging Ac-225 space reflects a deliberate portfolio strategy to control the PSMA RLT modality regardless of which radionuclide ultimately prevails.
Chelation Chemistry
ITM Isotope Technologies Munich SE has filed US patents on novel bifunctional chelating agents — specifically macropa-NH2 and crown ether variants — demonstrating superior kinetic inertness versus DOTA at physiological pH and temperature for Ac-225 complexation. These chelators are designed to prevent release of radioactive daughter radionuclides (Fr-221, Bi-213) that contribute to non-targeted tissue irradiation, addressing the fundamental safety limitation of DOTA-based Ac-225 labelling. ABX Advanced Biochemical Compounds has filed WO patents on next-generation PSMA-targeting ligands with structural modifications to the PSMA-617 scaffold that improve tumour-to-kidney and tumour-to-salivary gland ratios, with in vitro and in vivo data demonstrating tumour retention half-lives exceeding 18 hours with reduced off-target accumulation.
Isotope Production
Eckert and Ziegler SE holds WO patents on large-scale Ac-225 production methods via radium-226 proton irradiation at cyclotron facilities and linear accelerator approaches, including automated hot cell separation and daughter radionuclide recovery systems. This production-layer IP is strategically significant: control of isotope supply is as important as control of the therapeutic composition itself in determining who can bring Ac-225 PSMA therapy to commercial scale.
Combination Strategies and Novel Constructs
AstraZeneca PLC has filed US patents on combinations of Ac-225 PSMA alpha therapy with anti-PD-1, anti-PD-L1, and anti-CTLA-4 immune checkpoint inhibitors, grounded in the ICD mechanism described above. Fusion Pharmaceuticals holds US patents on bi-specific PSMA/FAP constructs compatible with both Lu-177 and Ac-225 labelling. Paul Scherrer Institute holds WO patents on alternative alpha emitters Tb-149 and Bi-213 as PSMA-targeting agents. The breadth of assignees — spanning large pharma (Bayer, Novartis, AstraZeneca), specialised radiopharmaceutical companies (ITM, RadioMedix, Eckert and Ziegler), and academic institutions (Paul Scherrer Institute) — reflects the genuinely multi-stakeholder nature of this emerging field, as tracked across platforms such as PatSnap's innovation intelligence database.
Key patent filers in the Ac-225 PSMA radioligand therapy space include Bayer AG, Novartis AG, RadioMedix Inc., ITM Isotope Technologies Munich SE, Eckert and Ziegler SE, AstraZeneca PLC, Fusion Pharmaceuticals Inc., ABX Advanced Biochemical Compounds GmbH, and Paul Scherrer Institute — covering therapeutic compositions, chelation chemistry, isotope production, and combination strategies.
It is important to note that this patent analysis is derived from a limited set of retrieved records and should not be interpreted as a comprehensive freedom-to-operate assessment or a complete competitive intelligence view. The WIPO global patent database and national patent offices including the USPTO and EPO contain the full scope of filings in this space. Readers requiring comprehensive landscape analysis are advised to use dedicated patent analytics tools.